Review of methods to remove protein-bound substances in liver failure

International Journal of Artificial Organs

Volumn 25, Issue 10, 2002, Pages 911-917

  Hughes, Robin D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Albumin; Albumin dialysis; Bile acids; Bilirubin; Liver failure; Liver support

Indexed keywords

ARTIFICIAL ORGANS; BODY FLUIDS; CELL DEATH; PROTEINS;

ALBUMIN; ALBUMIN DIALYSIS; BILE ACID; BILIRUBIN; LIVER FAILURE; LIVER SUPPORT; PLASMA PROTEIN; SERUM ALBUMIN; SOLUBLE SUBSTANCES; TOXIC SUBSTANCES;

DIALYSIS;

ACETYLSALICYLIC ACID; ALBUMIN; ANTIBIOTIC AGENT; APOLIPOPROTEIN D; AROMATIC AMINE; BENZODIAZEPINE; BENZOIC ACID DERIVATIVE; BILE ACID; BILIRUBIN; CHENODEOXYCHOLIC ACID; COPPER; CYTOKINE; DEOXYCHOLIC ACID; DIGOXIN; FATTY ACID; GLYCOPROTEIN; LIGAND; LIPID; NITRIC OXIDE; OCTANOIC ACID; PHENOLSULFONPHTHALEIN; PLASMA PROTEIN; PROTEIN; RESIN; SARCOSINE; THIOL;

ALBUMIN BLOOD LEVEL; APOPTOSIS; ARTIFICIAL LIVER; ASTROCYTE; BACTERIAL INFECTION; BILIARY EXCRETION; DIALYSIS; HEMOPERFUSION; HUMAN; IN VITRO STUDY; LIPID SOLUBILITY; LIVER CELL; LIVER FAILURE; MYCOSIS; NONHUMAN; PLASMAPHERESIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REVIEW;

EID: 0036816168     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202501003     Document Type: Review

References (39)

1. Hughes RD, Williams R. Clinical experience with charcoal and resin haemoperfusion. Semin Liver Dis 1986; 6: 164-73.
2. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186-92.
3. Dunlop EH, Hughes RD, Williams R. Physico-chemical aspects of the removal of protein-bound substances by charcoal and other adsorbents of potential value in systems of artificial liver support. Part 1 - Equilibrium properties. Med Biol Eng Comput 1978; 16: 343-9.
4. Ton HY, Hughes RD, Silk DBA, Williams R. Adsorption of human serum albumin to Amberlite XAD-7 resin. J Biomed Mater Res 1979; 13: 407-23.
5. Ton HY, Hughes RD, Silk DBA, Williams R. Albumin-coated Amberlite XAD-7 resin for haemoperfusion in acute liver failure. Part 1 - Adsorption studies. Artif Organs 1979; 3: 20-2.
6. Hughes RD, Ton HY, Langley PG, et al. Albumin-coated Amberlite XAD-7 resin for haemoperfusion in acute liver failure. Part 2 - In vivo evaluation. Artif Organs 1979; 3: 23-6.
7. Nagaki M, Hughes RD, Lau JYN, Williams R. Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Organs 1991; 14: 43-50.
8. Nagaki M, Hughes RD, Keane HM, Lau JYN, Williams R. In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circulatory Shock 1992; 38: 182-8.
9. Carter DC, Ho JX. Structure of human albumin. Adv Protein Chem 1994; 45: 152-203.
10. Brodersen R. Binding of bilirubin to albumin. CRC Crit Rev Clin Lab Sci 1980; 11: 305-99.
11. Sarnatskaya VV, Invanov AI, Nikolaev VG, et al. Structure and binding properties of serum albumin in uremic patients at different periods of hemodialysis. Artif Organs 1998; 22: 107-15.
12. Klammt S, Brinkmann B, Mitzner S, et al. Assessment of the albumin binding capacity (ABIC) as a marker of albumin transport function by a new method. J Hepatol 2001; 34 (suppl 1): S197.
13. Goessling W, Zucker SD. Role of apolipoprotein D in transport of bilirubin in plasma. Am J Physiol Liver Physiol 2000; 279: G356-65.
14. Haga Y, Tempero MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochim Biophys Acta 1996; 7: 65-70.
15. Silva R, Mata LR, Gulbenkian S, Brito MA, Tiribelli C, Brites D. Inhibition of glutamate uptake by unconjugated bilirubin in cultured cortical astrocytes: Role of concentration and pH. Biochem Biophys Res Commun 1999; 265: 67-72.
16. Silva RFM, Rodrigues CMP, Brites D. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic acid but prevented by ursodeoxycholic acid. J Hepatol 2001; 34: 402-8.
17. Hughes RD, Cochrane AMG, Thomson AD, Murray-Lyon IM, Williams R. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol 1976; 57: 348-53.
18. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790-9.
19. Larsen FS, Hansen BA, Jorgensen LG, et al. Cerebral blood flow velocity during high volume plasmapheresis in fulminant hepatic failure. Int J Artif Organs 1994; 17: 353-61.
20. Clemmensen JO, Gerbes AL, Gulberg V, et al. Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure. Effect of high volume plasmapheresis. Hepatology 1999; 29: 347-55.
21. Tygstrup N, Larsen FS, Hansen BA. Treatment of acute liver failure by high volume plasmapheresis. In: Lee WM, Williams R, eds. Acute Liver Failure. Cambridge University Press, 1997, 267-77.
22. Iwai H, Nagaki M, Naito T, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998; 26: 873-6.
23. Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-30.
24. Mitzner SR, Stange J, Klammt S, et al. Liver support by extracorporeal blood purification: A clinical observation. Liver Transpl 2000; 6: 603-13.
25. Kreymann B, Seige M, Schweigart U, Kopp K-F, Classen M. Albumin dialysis: Effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31: 1080-5.
26. Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-62.
27. Falkenhagen D, Strobl W Vogt G, et al. Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23: 81-6.
28. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994; 17: 657-62.
29. Ash SR, Steczko J, Knab WR, et al. Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: Preliminary results of a clinical trial with the BioLogic-DTPF system. Ther Apher 2000; 4: 218-28.
30. Chari RS, Collins BH, Magee JC, et al. Brief report: Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. New Engl J Med 1994; 331: 234-7.
31. Horslen SP, Hammel JM, Fristoe LW, et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000; 70: 1472-8.
32. Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis 1996; 16: 435-44.
33. Busse B, Smith MD, Gerlach JC. Treatment of acute liver failure: Hybrid liver support. A critical overview. Langenbeck's Arch Surg 1999; 383: 588-99.
34. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001; 34: 447-55.
35. Stevens AC, Busuttil R, Han S, et al. An interim analysis of a phase II/III prospective randomized multicenter, controlled trial of the Hepatoassist bioartificial liver support system for the treatment of fulminant hepatic failure. Hepatology 2001; (suppl 34): S509.
36. Arkadopoulos N, Detry O, Rozga J, Demetriou AA. Liver assist systems: State of the art. Int J Artif Organs 1998; 21: 781-7.
37. Ellis AJ, Wendon JA, Hughes RD, et al. Pilot controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446-51.
38. Hughes RD, Nicolaou N, Langley PG, Ellis AJ, Wendon JA, Williams R. Plasma cytokine levels and coagulation and complement activation during treatment with the ELAD in acute liver failure. Artif Organs 1998; 10: 854-8.
39. Millis JM, Cronin DC, Johnson R, et al. Safety of continuous human liver support. Transplant Proc 2001; 33: 1954.